AGP Picks
View all

Times Reporter of Africa: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Times Reporter of Africa.

Press releases published on November 18, 2026

Horizon Vista Hospitality Introduces Its Brand and Vision With Inaugural Holiday Gala at The Watergate Hotel
Nexora Securities Intègre le Suivi des Marchés Internationaux et de la BRVM pour Soutenir l'Analyse Transfrontalière
Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Northern Discovery Metals Lists on the OTCQB Venture Market
Onco360® Has Been Selected as a National Pharmacy Partner for PIMJETMI® (pimicotinib)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026
Quorum Software Launches Quorum Qnect AI Platform to Connect Data Across the  Energy Value Chain
Sanku to Open Nutrient Premix Factory on Dec. 7, Bringing Local Manufacturing to Ethiopia
VAST Data Wins Three 2026 HPCwire Readers’ and Editors’ Choice Awards Recognizing Leadership in AI Infrastructure
VAST Data Solves Longstanding I/O Contention Challenge Without Interrupting Running Jobs
Apimeds Pharmaceuticals US Reports Third Quarter 2026 Results, Delivers First Operating Revenue from Technology Services
AIM ImmunoTech Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
SELLAS Life Sciences meldet positive Ergebnisse der zulassungsrelevanten Phase III-Studie REGAL zu immuntherapeutischem Krebsimpfstoff Galinpepimut-S (GPS), die eine statistisch signifikante und klinisch bedeutsame Verbesserung in Bezug auf…
SELLAS Life Sciences annonce une les résultats positifs de l’étude pivot de phase III REGAL : l’utilisation du vaccin immunothérapeutique contre le cancer, le Galinpepimut-S (GPS), a démontré une amélioration statistiquement significative et…
חברת SELLAS Life Sciences מודיעה על נתונים חיוביים מניסוי ה-REGAL – מחקר מכריע בשלב 3 – המראים כי החיסון האימונותרפי לסרטן, Galinpepimut-S (GPS), הוביל לשיפור מובהק סטטיסטית ומשמעותי מבחינה קלינית בהישרדות הכוללת בקרב חולים עם לוקמיה מיאלואידית חריפה (…
SELLAS Life Sciences Mengumumkan Data Positif dari Uji Klinis Penting Fase 3 REGAL yang Menunjukkan bahwa Vaksin Imunoterapi Kanker Galinpepimut-S (GPS) Memberikan Peningkatan Kesintasan Keseluruhan yang Signifikan Secara Statistik dan Bermakna Secara…

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Times Reporter of Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.